This large population-based cohort study evaluated the relationship between metabolic syndrome (MetS) and the risk of cholangiocarcinoma (CCA), including both intrahepatic and extrahepatic subtypes. The study included nearly 4.
This large population-based cohort study evaluated the relationship between metabolic syndrome (MetS) and the risk of cholangiocarcinoma (CCA), including both intrahepatic and extrahepatic subtypes.
The study included nearly 4.9 million adults aged ≥40 years who underwent national health screening between 2012 and 2017, with follow-up through 2021. Over 35.9 million person-years, 6,117 cases of CCA were identified.
Individuals with metabolic syndrome had a 20% higher risk of cholangiocarcinoma compared with those without MetS (adjusted HR 1.20). The increased risk was consistent across subgroups defined by age, sex, liver enzyme levels, and comorbidities. Importantly, the association applied to both intrahepatic and extrahepatic CCA.
A clear dose–response relationship was observed: the more metabolic components present (central obesity, hypertension, hyperglycemia, dyslipidemia), the higher the CCA risk. Individuals with five metabolic components had a 67% increased risk compared with those without metabolic abnormalities. These findings remained robust after accounting for the competing risk of all-cause mortality.
Clinical implication: Metabolic syndrome is not only a cardiovascular and hepatometabolic concern but also an independent risk factor for biliary tract malignancy. Aggressive management of metabolic risk factors may have potential implications for reducing cholangiocarcinoma incidence.
Introduction: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited improvements in survival despite the addition of immune checkpoint inhibitors to standard gemcitabine–cisplatin chemotherapy. This phase II trial evaluated ivonescimab, a novel PD-1/VEGF...
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in the management of type 2 diabetes because of their excellent glycemic, cardiovascular, and weight-loss benefits. However, concerns remain regarding their potential association with...
Introduction: Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during...
• This study evaluated 1,063 patients undergoing pancreatic surgery; 11% developed conventionally defined chyle leak. • Most clinically relevant cases were grade B, while no grade C leaks were reported. • A minimally invasive surgical...
Introduction: Endoscopic ultrasound (EUS)-guided drainage has become the preferred minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Fatty pancreas disease (FPD), also known as intrapancreatic fat deposition, has emerged as an important metabolic condition closely linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Although ectopic fat accumulation in...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.